全球急性间歇性卟啉症市场研究报告 - 2024 年至 2032 年产业分析、规模、份额、成长、趋势与预测

全球急性间歇性卟啉症市场需求预计将从 2023 年的 563 万美元达到 2032 年近 841 万美元的市场规模，2024-2032 年研究期间复合年增长率为 4.56%。

急性间歇性卟啉症 (AIP) 是一种罕见的遗传性疾病，会影响血红素（血红素的一种成分）的产生。突然发作的腹痛、呕吐、神经系统失调以及焦虑或幻觉等心理症状是其特征。某些药物、荷尔蒙变化或饮食因素通常会引发这些发作。诊断包括检测尿液中胆色素原和δ-氨基乙酰丙酸水平升高。治疗包括避免诱发因素、发作期间的症状治疗，有时还需要使用血红素输注。

市场动态

急性间歇性卟啉症市场受到对罕见遗传性疾病的认识和诊断不断提高的影响，从而改善了疾病管理和治疗选择。此外，医学研究和基因检测技术的进步使医疗保健提供者能够更好地了解急性间歇性卟啉症的根本原因和机制，从而促进早期检测和介入。此外，製药公司和学术机构之间的合作推动了研发工作，以发现新疗法并改善治疗选择。然而，有限的治疗选择和管理急性发作的复杂性等挑战可能会影响未来几年的市场成长。随着医疗保健提供者和研究人员努力为罕见疾病患者提供更好的治疗结果和生活质量，对急性间歇性卟啉症的有效治疗和管理策略的需求预计将推动市场的进一步发展。

研究报告涵盖波特五力模型、市场吸引力分析和价值链分析。这些工具有助于清晰地了解行业结构并评估全球范围内的竞争吸引力。此外，这些工具也对全球急性间歇性卟啉症市场的各个细分市场进行了包容性评估。急性间歇性卟啉症产业的成长和趋势为本研究提供了整体方法。

市场区隔

急性间歇性卟啉症市场报告的这一部分提供了有关国家和区域层面细分市场的详细资料，从而帮助策略师确定相应产品或服务的目标人口统计数据以及即将到来的机会。

透过诊断

• 验血
• 尿液检查
• 脱氧核糖核酸测试
• 血清检测

按治疗

• 促性腺激素释放激素类似物
• 预防性血红素输注

按最终用户

• 医院
• 诊所
• 研究中心

区域分析

本节涵盖区域前景，重点介绍北美、欧洲、亚太地区、拉丁美洲以及中东和非洲的急性间歇性卟啉症市场当前和未来的需求。此外，该报告重点关注所有主要地区各个应用领域的需求、估计和预测。

该研究报告还涵盖了市场主要参与者的全面概况以及对全球竞争格局的深入了解。急性间歇性卟啉症市场的主要参与者包括 Alnylam Pharmaceuticals Inc.、Clinuvel Pharmaceuticals Ltd.、BioMarin Pharmaceutical Inc.、Recordati、Quest Diagnostics、Invitae Corp.、Laboratory Corporation Of America Holdings (Labcorp) 和 ARUP Laboratories。本节包含竞争格局的整体视图，包括各种策略发展，例如关键併购、未来产能、合作伙伴关係、财务概况、合作、新产品开发、新产品发布和其他发展。

如果您有任何客製化要求，请写信给我们。我们的研究团队可以根据您的需求提供客製化报告。

目录

第一章：前言

• 报告说明
  • 客观的
  • 目标受众
  • 独特的销售主张 (USP) 和产品
• 研究范围
• 研究方法论
  • 市场研究过程
  • 市场研究方法论

第 2 章：执行摘要

• 市集亮点
• 全球市场概况

第 3 章：急性间歇性卟啉症 - 产业分析

• 简介 - 市场动态
• 市场驱动因素
• 市场限制
• 机会
• 产业动态
• 波特五力分析
• 市场吸引力分析
  • 市场吸引力诊断分析
  • 按处理方式进行的市场吸引力分析
  • 最终用户的市场吸引力分析
  • 市场吸引力分析：按地区

第 4 章：价值链分析

• 价值链分析
• 原料分析
  • 原料清单
  • 原料厂商清单
  • 主要原物料价格走势
• 潜在买家名单
• 行销管道
  • 直效行销
  • 间接行销
  • 行销通路发展趋势

第 5 章：全球急性间歇性卟啉症市场分析：透过诊断

• 诊断概述
• 历史和预测数据
• 诊断分析
• 验血
• 尿液检查
• 脱氧核糖核酸测试
• 血清检测

第 6 章：全球急性间歇性卟啉症市场分析：依治疗分类

• 按治疗概述
• 历史和预测数据
• 治疗分析
• 促性腺激素释放激素类似物
• 预防性血红素输注

第 7 章：全球急性间歇性卟啉症市场分析：依最终使用者分类

• 最终用户概述
• 历史和预测数据
• 最终用户分析
• 医院
• 诊所
• 研究中心

第 8 章：全球急性间歇性卟啉症市场分析：依地理位置

• 区域展望
• 介绍
• 北美销售分析
  • 概览、历史与预测资料销售分析
  • 北美按细分市场销售分析
  • 北美按国家销售分析
  • 美国销售分析
  • 加拿大销售分析
  • 墨西哥销售分析
• 欧洲销售分析
  • 概览、历史与预测资料销售分析
  • 欧洲按细分市场销售分析
  • 欧洲按国家销售分析
  • 英国销售分析
  • 法国销售分析
  • 德国销售分析
  • 义大利销售分析
  • 俄罗斯销售分析
  • 欧洲其他地区销售分析
• 亚太地区销售分析
  • 概览、历史与预测资料销售分析
  • 亚太地区按细分市场销售分析
  • 亚太地区按国家销售分析
  • 中国销售分析
  • 印度销售分析
  • 日本销售分析
  • 韩国销售分析
  • 澳洲销售分析
  • 东南亚销售分析
  • 亚太地区其他地区销售分析
• 拉丁美洲销售分析
  • 概览、历史与预测资料销售分析
  • 拉丁美洲按细分市场销售分析
  • 拉丁美洲按国家销售分析
  • 巴西销售分析
  • 阿根廷销售分析
  • 秘鲁销售分析
  • 智利销售分析
  • 拉丁美洲其他地区销售分析
• 中东和非洲销售分析
  • 概览、历史与预测资料销售分析
  • 中东和非洲按细分市场销售分析
  • 中东和非洲按国家销售分析
  • 沙乌地阿拉伯销售分析
  • 阿联酋销售分析
  • 以色列销售分析
  • 南非销售分析
  • 中东其他地区和非洲销售分析

第 9 章：急性间歇性卟啉症公司的竞争格局

• 急性间歇性卟啉症市场竞争
• 伙伴关係/协作/协议
• 併购
• 新产品发布
• 其他发展

第 10 章：公司简介

• 顶级公司市占率分析
• 市场集中度
• Alnylam Pharmaceuticals Inc.
• 公司简介
• 公司收入
• 产品
• 最近的发展
• Clinuvel Pharmaceuticals Ltd.
• 公司简介
• 公司收入
• 产品
• 最近的发展
• BioMarin Pharmaceutical Inc.
• 公司简介
• 公司收入
• 产品
• 最近的发展
• Recordati
• 公司简介
• 公司收入
• 产品
• 最近的发展
• Quest Diagnostics
• 公司简介
• 公司收入
• 产品
• 最近的发展
• Invitae Corp.
• 公司简介
• 公司收入
• 产品
• 最近的发展
• Laboratory Corporation Of America Holdings (Labcorp)
• 公司简介
• 公司收入
• 产品
• 最近的发展
• ARUP Laboratories
• 公司简介
• 公司收入
• 产品
• 最近的发展

註 - 在公司概况中，财务详细资料和最新进展视情况而定，或对私人公司而言可能不包括在内

The global demand for Acute Intermittent Porphyria Market is presumed to reach the market size of nearly USD 8.41 Million by 2032 from USD 5.63 Million in 2023 with a CAGR of 4.56% under the study period 2024-2032.

Acute intermittent porphyria (AIP) is a rare genetic disorder that affects heme production, a hemoglobin component. Sudden attacks of abdominal pain, vomiting, neurological disturbances, and psychological symptoms like anxiety or hallucinations characterize it. Certain medications, hormonal changes, or dietary factors often trigger these attacks. Diagnosis involves detecting elevated levels of porphobilinogen and delta-aminolevulinic acid in the urine. Management includes avoiding triggers, symptomatic treatment during attacks, and sometimes the use of heme infusions.

MARKET DYNAMICS

The acute intermittent porphyria market is influenced by the increasing awareness and diagnosis of rare genetic disorders, leading to improved disease management and treatment options. Additionally, advancements in medical research & genetic testing technologies enable healthcare providers to understand better the underlying causes and mechanisms of acute intermittent porphyria, facilitating earlier detection and intervention. Moreover, collaborations among pharmaceutical companies and academic institutions drive research & development efforts to discover novel therapies and improve treatment options. However, challenges such as limited treatment options and the complexity of managing acute attacks may impact the market growth in the coming years. As healthcare providers and researchers strive for better outcomes and quality of life for patients with rare diseases, the demand for effective treatments and management strategies for acute intermittent porphyria is expected to drive further market development.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of Acute Intermittent Porphyria. The growth and trends of Acute Intermittent Porphyria industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the Acute Intermittent Porphyria market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Diagnosis

• Blood Test
• Urine Test
• DNA Test
• Serum Test

By Treatment

• Gonadotropin-Releasing Hormone Analogues
• Prophylactic Hematin Infusions

By End-user

• Hospitals
• Clinics
• Research Centers

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Acute Intermittent Porphyria market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Acute Intermittent Porphyria market include Alnylam Pharmaceuticals Inc., Clinuvel Pharmaceuticals Ltd., BioMarin Pharmaceutical Inc., Recordati, Quest Diagnostics, Invitae Corp., Laboratory Corporation Of America Holdings (Labcorp), ARUP Laboratories. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1. PREFACE

• 1.1. Report Description
  • 1.1.1 Objective
  • 1.1.2 Target Audience
  • 1.1.3 Unique Selling Proposition (USP) & offerings
• 1.2. Research Scope
• 1.3. Research Methodology
  • 1.3.1 Market Research Process
  • 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

• 2.1. Highlights of Market
• 2.2. Global Market Snapshot

3. ACUTE INTERMITTENT PORPHYRIA - INDUSTRY ANALYSIS

• 3.1. Introduction - Market Dynamics
• 3.2. Market Drivers
• 3.3. Market Restraints
• 3.4. Opportunities
• 3.5. Industry Trends
• 3.6. Porter's Five Force Analysis
• 3.7. Market Attractiveness Analysis
  • 3.7.1 Market Attractiveness Analysis By Diagnosis
  • 3.7.2 Market Attractiveness Analysis By Treatment
  • 3.7.3 Market Attractiveness Analysis By End-user
  • 3.7.4 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

• 4.1. Value Chain Analysis
• 4.2. Raw Material Analysis
  • 4.2.1 List of Raw Materials
  • 4.2.2 Raw Material Manufactures List
  • 4.2.3 Price Trend of Key Raw Materials
• 4.3. List of Potential Buyers
• 4.4. Marketing Channel
  • 4.4.1 Direct Marketing
  • 4.4.2 Indirect Marketing
  • 4.4.3 Marketing Channel Development Trend

5. GLOBAL ACUTE INTERMITTENT PORPHYRIA MARKET ANALYSIS BY DIAGNOSIS

• 5.1. Overview By Diagnosis
• 5.2. Historical and Forecast Data
• 5.3. Analysis By Diagnosis
• 5.4. Blood Test Historic and Forecast Sales By Regions
• 5.5. Urine Test Historic and Forecast Sales By Regions
• 5.6. DNA Test Historic and Forecast Sales By Regions
• 5.7. Serum Test Historic and Forecast Sales By Regions

6. GLOBAL ACUTE INTERMITTENT PORPHYRIA MARKET ANALYSIS BY TREATMENT

• 6.1. Overview By Treatment
• 6.2. Historical and Forecast Data
• 6.3. Analysis By Treatment
• 6.4. Gonadotropin-Releasing Hormone Analogues Historic and Forecast Sales By Regions
• 6.5. Prophylactic Hematin Infusions Historic and Forecast Sales By Regions

7. GLOBAL ACUTE INTERMITTENT PORPHYRIA MARKET ANALYSIS BY END-USER

• 7.1. Overview By End-user
• 7.2. Historical and Forecast Data
• 7.3. Analysis By End-user
• 7.4. Hospitals Historic and Forecast Sales By Regions
• 7.5. Clinics Historic and Forecast Sales By Regions
• 7.6. Research Centers Historic and Forecast Sales By Regions

8. GLOBAL ACUTE INTERMITTENT PORPHYRIA MARKET ANALYSIS BY GEOGRAPHY

• 8.1. Regional Outlook
• 8.2. Introduction
• 8.3. North America Sales Analysis
  • 8.3.1 Overview, Historic and Forecast Data Sales Analysis
  • 8.3.2 North America By Segment Sales Analysis
  • 8.3.3 North America By Country Sales Analysis
  • 8.3.4 United States Sales Analysis
  • 8.3.5 Canada Sales Analysis
  • 8.3.6 Mexico Sales Analysis
• 8.4. Europe Sales Analysis
  • 8.4.1 Overview, Historic and Forecast Data Sales Analysis
  • 8.4.2 Europe By Segment Sales Analysis
  • 8.4.3 Europe By Country Sales Analysis
  • 8.4.4 United Kingdom Sales Analysis
  • 8.4.5 France Sales Analysis
  • 8.4.6 Germany Sales Analysis
  • 8.4.7 Italy Sales Analysis
  • 8.4.8 Russia Sales Analysis
  • 8.4.9 Rest Of Europe Sales Analysis
• 8.5. Asia Pacific Sales Analysis
  • 8.5.1 Overview, Historic and Forecast Data Sales Analysis
  • 8.5.2 Asia Pacific By Segment Sales Analysis
  • 8.5.3 Asia Pacific By Country Sales Analysis
  • 8.5.4 China Sales Analysis
  • 8.5.5 India Sales Analysis
  • 8.5.6 Japan Sales Analysis
  • 8.5.7 South Korea Sales Analysis
  • 8.5.8 Australia Sales Analysis
  • 8.5.9 South East Asia Sales Analysis
  • 8.5.10 Rest Of Asia Pacific Sales Analysis
• 8.6. Latin America Sales Analysis
  • 8.6.1 Overview, Historic and Forecast Data Sales Analysis
  • 8.6.2 Latin America By Segment Sales Analysis
  • 8.6.3 Latin America By Country Sales Analysis
  • 8.6.4 Brazil Sales Analysis
  • 8.6.5 Argentina Sales Analysis
  • 8.6.6 Peru Sales Analysis
  • 8.6.7 Chile Sales Analysis
  • 8.6.8 Rest of Latin America Sales Analysis
• 8.7. Middle East & Africa Sales Analysis
  • 8.7.1 Overview, Historic and Forecast Data Sales Analysis
  • 8.7.2 Middle East & Africa By Segment Sales Analysis
  • 8.7.3 Middle East & Africa By Country Sales Analysis
  • 8.7.4 Saudi Arabia Sales Analysis
  • 8.7.5 UAE Sales Analysis
  • 8.7.6 Israel Sales Analysis
  • 8.7.7 South Africa Sales Analysis
  • 8.7.8 Rest Of Middle East And Africa Sales Analysis

9. COMPETITIVE LANDSCAPE OF THE ACUTE INTERMITTENT PORPHYRIA COMPANIES

• 9.1. Acute Intermittent Porphyria Market Competition
• 9.2. Partnership/Collaboration/Agreement
• 9.3. Merger And Acquisitions
• 9.4. New Product Launch
• 9.5. Other Developments

10. COMPANY PROFILES OF ACUTE INTERMITTENT PORPHYRIA INDUSTRY

• 10.1. Top Companies Market Share Analysis
• 10.2. Market Concentration Rate
• 10.3. Alnylam Pharmaceuticals Inc.
  • 10.3.1 Company Overview
  • 10.3.2 Company Revenue
  • 10.3.3 Products
  • 10.3.4 Recent Developments
• 10.4. Clinuvel Pharmaceuticals Ltd.
  • 10.4.1 Company Overview
  • 10.4.2 Company Revenue
  • 10.4.3 Products
  • 10.4.4 Recent Developments
• 10.5. BioMarin Pharmaceutical Inc.
  • 10.5.1 Company Overview
  • 10.5.2 Company Revenue
  • 10.5.3 Products
  • 10.5.4 Recent Developments
• 10.6. Recordati
  • 10.6.1 Company Overview
  • 10.6.2 Company Revenue
  • 10.6.3 Products
  • 10.6.4 Recent Developments
• 10.7. Quest Diagnostics
  • 10.7.1 Company Overview
  • 10.7.2 Company Revenue
  • 10.7.3 Products
  • 10.7.4 Recent Developments
• 10.8. Invitae Corp.
  • 10.8.1 Company Overview
  • 10.8.2 Company Revenue
  • 10.8.3 Products
  • 10.8.4 Recent Developments
• 10.9. Laboratory Corporation Of America Holdings (Labcorp)
  • 10.9.1 Company Overview
  • 10.9.2 Company Revenue
  • 10.9.3 Products
  • 10.9.4 Recent Developments
• 10.10. ARUP Laboratories
  • 10.10.1 Company Overview
  • 10.10.2 Company Revenue
  • 10.10.3 Products
  • 10.10.4 Recent Developments

Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of private companies

LIST OF TABLES

• Market Snapshot
• Drivers: Impact Analysis
• Restraints: Impact Analysis
• List of Raw Material
• List of Raw Material Manufactures
• Analysis By Diagnosis (USD MN)
• Blood Test Market Sales By Geography (USD MN)
• Urine Test Market Sales By Geography (USD MN)
• DNA Test Market Sales By Geography (USD MN)
• Serum Test Market Sales By Geography (USD MN)
• Analysis By Treatment (USD MN)
• Gonadotropin-Releasing Hormone Analogues Market Sales By Geography (USD MN)
• Prophylactic Hematin Infusions Market Sales By Geography (USD MN)
• Analysis By End-user (USD MN)
• Hospitals Market Sales By Geography (USD MN)
• Clinics Market Sales By Geography (USD MN)
• Research Centers Market Sales By Geography (USD MN)
• Global Acute Intermittent Porphyria Market Sales By Geography (USD MN)
• North America Market Analysis (USD MN)
• United States Market Analysis (USD MN)
• Canada Market Analysis (USD MN)
• Mexico Market Analysis (USD MN)
• Europe Market Analysis (USD MN)
• Europe Market Estimate By Country (USD MN)
• United Kingdom Market Analysis (USD MN)
• France Market Analysis (USD MN)
• Germany Market Analysis (USD MN)
• Italy Market Analysis (USD MN)
• Russia Market Analysis (USD MN)
• Spain Market Analysis (USD MN)
• Rest of Europe Market Analysis (USD MN)
• Asia Pacific Market Analysis (USD MN)
• China Market Analysis (USD MN)
• Japan Market Analysis (USD MN)
• India Market Analysis (USD MN)
• South Korea Market Analysis (USD MN)
• Australia Market Analysis (USD MN)
• South East Asia Market Analysis (USD MN)
• Rest of Asia Pacific Market Analysis (USD MN)
• Latin America Market Analysis (USD MN)
• Brazil Market Analysis (USD MN)
• Argentina Market Analysis (USD MN)
• Peru Market Analysis (USD MN)
• Chile Market Analysis (USD MN)
• Rest of Latin America Market Analysis (USD MN)
• Middle East & Africa Market Analysis (USD MN)
• Saudi Arabia Market Analysis (USD MN)
• UAE Market Analysis (USD MN)
• Israel Market Analysis (USD MN)
• South Africa Market Analysis (USD MN)
• Rest of Middle East and Africa Market Analysis (USD MN)
• Partnership/Collaboration/Agreement
• Mergers And Acquisition

LIST OF FIGURES

• Research Scope of Acute Intermittent Porphyria Report
• Market Research Process
• Market Research Methodology
• Global Acute Intermittent Porphyria Market Size, By Region (USD MN)
• Porters Five Forces Analysis
• Market Attractiveness Analysis By Diagnosis
• Market Attractiveness Analysis By Treatment
• Market Attractiveness Analysis By End-user
• Market Attractiveness Analysis By Region
• Value Chain Analysis
• Global Market Analysis By Diagnosis (USD MN)
• Blood Test Market Sales By Geography (USD MN)
• Urine Test Market Sales By Geography (USD MN)
• DNA Test Market Sales By Geography (USD MN)
• Serum Test Market Sales By Geography (USD MN)
• Global Market Analysis By Treatment (USD MN)
• Gonadotropin-Releasing Hormone Analogues Market Sales By Geography (USD MN)
• Prophylactic Hematin Infusions Market Sales By Geography (USD MN)
• Global Market Analysis By End-user (USD MN)
• Hospitals Market Sales By Geography (USD MN)
• Clinics Market Sales By Geography (USD MN)
• Research Centers Market Sales By Geography (USD MN)
• Global Market Sales (USD MN)
• North America Market Sales (USD MN)
• Europe Market Sales (USD MN)
• Asia Pacific Market Sales (USD MN)
• Latin America Market Sales (USD MN)
• Middle East & Africa Market Sales (USD MN)
• Recent Development in Industry
• Top Company Market Share Analysis

Kindly note that the above listed are the basic tables and figures of the report and are not limited to the TOC.